HIK Hikma Pharmaceuticals Plc

TIDMHIK

RNS Number : 7668Q

Hikma Pharmaceuticals Plc

23 June 2020

23 June 2020

Hikma Pharmaceuticals PLC ("Hikma" or the "Company")

Transaction in Own Shares and Total Voting Rights and Capital

Further to the announcements by Hikma and Boehringer Ingelheim Invest GmbH ("Boehringer Ingelheim") on 22(nd) June 2020, Hikma today announces the Company has entered into arrangements to buy back approximately 12.8 million ordinary shares (the "Buy Back Shares") currently owned by Boehringer Ingelheim (the "Buy Back") at a price per Buy Back Share of GBP23.00 (the "Buy Back Price"). Hikma will receive a commitment fee from Boehringer Ingelheim of 2 per cent. of the aggregate value of the Buy Back Shares acquired at the Buy Back Price . Citigroup Global Markets Limited ("Citi") is acting as riskless principal for the purpose of the Buy Back.

The Buy Back Shares will all be held as treasury shares. Following the Buy Back, the Company's share capital consists of 243,283,072 ordinary shares carrying voting rights, of which 12,833,233 (5.3%) ordinary shares are held in treasury. The voting rights attaching to the treasury shares are not capable of exercise. Therefore the total number of the voting rights in the Company (after excluding the treasury shares) is 230,449,839 ("Total Voting Rights").

The Total Voting Rights figure (230,449,839) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Citi and Goldman Sachs International ("Goldman Sachs") are acting as joint financial advisers to Hikma on the Buy Back.

Enquiries:

 
 Hikma 
 Susan Ringdal                                  +44 (0)20 7399 2760/+44 
  EVP, Strategic Planning and Global Affairs     (0)7776 477050 
 Guy Featherstone                               +44 (0)20 3892 4389/+44 
  Senior Investor Relations Manager              (0)7795 896738 
 
 Citi (Financial Adviser and Corporate 
  Broker to Hikma)                              +44 (0)20 7986 4000 
 Andrew Seaton 
 Robert Way 
 Suneel Hargunani 
 
 Goldman Sachs (Financial Adviser to Hikma)     +44 (0)20 7774 1000 
 Robert King 
 John Wilkinson 
 Christoph Stanger 
 
 Teneo (Public Relations Adviser to Hikma) 
 Charles Armitstead                             +44 (0)7703 330 269 
 Camilla Cunningham                             +44 (0)7464 982 426 
 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and BB+/positive S&P)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

(c)2020 Hikma Pharmaceuticals PLC. All rights reserved.

Disclaimer

Citi, which is authorised by the Prudential Regulation Authority and regulated in the UK by the Financial Conduct Authority and the Prudential Regulation Authority is acting as financial adviser and corporate broker to Hikma and for no one else in connection with the Buy Back and other matters described in this announcement, and will not be responsible to anyone other than Hikma for providing the protections afforded to its clients nor for providing advice in relation to the Buy Back or any other matters referred to in this announcement. Neither Citi nor any of its affiliates, directors or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, consequential, whether in contract, tort, in delict, under statute or otherwise) to any person who is not a client of Citi in connection with this announcement, any statement contained herein, the Buy Back or otherwise.

Goldman Sachs, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting as financial adviser to Hikma and no one else in connection with the Buy Back and will not be responsible to anyone other than Hikma for providing the protections afforded to clients of Goldman Sachs International or for providing advice in connection with the Buy Back or in this Announcement or any transaction or arrangement referred to herein.

Further Information

This communication is not intended to and does not constitute an offer to buy or the solicitation of an offer to subscribe for or sell or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction. The release, publication or distribution of this communication in whole or in part, directly or indirectly, in, into or from certain jurisdictions may be restricted by law and therefore persons in such jurisdictions should inform themselves about and observe such restrictions.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdictions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

POSEXLBLBQLXBBX

(END) Dow Jones Newswires

June 23, 2020 02:00 ET (06:00 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024